Lymphoma
If it’s your first time on this website, please read the disclaimer section.
Jul 13 – Jul 20, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This secondary analysis of the TRIANGLE trial evaluated the efficacy and safety of adding rituximab maintenance (RM) to ibrutinib-containing regimens for younger, treatment-naïve patients with mantle cell lymphoma. Results demonstrated that RM significantly improved 4-year progression-free survival (PFS) in both the ibrutinib-only arm (85% vs 73%, p=.003) and the ibrutinib plus autologous stem-cell transplantation arm (90% vs 75%, p<.001). While RM showed a trend toward improved overall survival, it was associated with a higher risk of grade 3 to 5 infectious toxicities, reaching up to 41% in the transplant group. These findings support incorporating RM into BTK inhibitor-based protocols to achieve prolonged remission in this specific oncological population, despite the increased risk of infection.
10.1200/JCO-26-00705
Jul 06 – Jul 13, 2026
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This Phase III randomized trial (POLARGO) evaluated the efficacy and safety of adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) in 255 transplant-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma. Results demonstrated a significant improvement in overall survival for the Pola-R-GemOx group compared to R-GemOx alone, with a median survival of 19.5 months versus 12.5 months (HR 0.6; p = .0017). While efficacy was superior, the Pola-R-GemOx arm showed higher rates of peripheral neuropathy (57% vs. 29%) and fatal adverse events (12% vs. 4%), primarily driven by infections. These findings establish Pola-R-GemOx as a viable and effective treatment option for this high-risk cancer population, provided clinicians carefully manage the increased risk of toxicity.
10.1200/JCO-25-02849
Jun 29 – Jul 06, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase I/II study evaluated sonrotoclax monotherapy in 125 heavily pretreated patients with relapsed/refractory mantle cell lymphoma (MCL). The overall response rate by independent review committee (ORR-IRC) was 52.4% (p < .0001 vs. historic control), with a 15.5% complete response rate. Responses were durable, with a median duration of response of 15.8 months, and the drug demonstrated a manageable safety profile. These findings suggest sonrotoclax offers rapid, durable responses in a high-risk, pretreated MCL population, supporting its potential as a new oral therapeutic option for patients with relapsed/refractory MCL.
10.1200/JCO-26-00550
Extranodal natural killer/T-cell lymphoma: From fatal to curable.
CA-CANCER J CLIN · Q1 JOURNAL - RANK #1/326TOP-TIER
This review examines the therapeutic evolution of extranodal natural killer/T-cell lymphoma (ENKTCL), an aggressive Epstein-Barr virus-associated malignancy prevalent in Asian and South American populations. Current standard care utilizing combined-modality therapies targeting genomic and metabolic vulnerabilities has shifted the prognosis, with nearly 80% of newly diagnosed patients now achieving long-term survival. The study highlights the transition from ineffective anthracycline-based regimens to precision approaches, including hematopoietic stem cell transplantation for high-risk cases and novel agents targeting oncogenic signaling. Future management focuses on overcoming relapsed/refractory disease through EBV-targeted cellular therapies and vaccines, aiming to transform this once-fatal cancer into a consistently curable condition.
10.3322/caac.70094
Jun 22 – Jun 29, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This single-arm study evaluated 10-year outcomes after a single infusion of tisagenlecleucel (CTL019) in 38 patients with relapsed/refractory B-cell non-Hodgkin lymphomas (24 large B-cell, 14 follicular). Median follow-up was 10.1 years, with no relapses occurring beyond 5.4 years. Ten-year lymphoma-free survival was 32% (95% CI 14-51) for large B-cell lymphoma and 47% (95% CI 20-71) for follicular lymphoma; overall survival was 17% and 50%, respectively. For clinicians focused on cancer, these findings demonstrate durable remissions and long-term disease control, though second primary cancers (21% cumulative incidence) and persistent B-cell aplasia were notable.
10.1056/NEJMoa2518035
Jun 15 – Jun 22, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 3, double-blind, placebo-controlled trial (frontMIND) evaluated tafasitamab plus lenalidomide with R-CHOP versus R-CHOP alone in 899 patients with high-risk diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma. At a median follow-up of 35.2 months, progression-free survival (PFS) was significantly improved with tafa-len-R-CHOP (HR 0.75; 95% CI 0.59-0.96; p=0.0194), yielding 2-year PFS rates of 71.1% versus 62.9%. Overall survival data are immature (HR 0.85 [0.63-1.14]), but there were fewer total deaths (82 vs 97) despite higher grade ≥3 adverse events (87% vs 76%) and treatment-related deaths (6% vs 4%) in the experimental arm. For clinicians treating high-risk DLBCL, this combination offers a meaningful PFS benefit but with increased toxicity, warranting careful patient selection and monitoring.
10.1016/S0140-6736(26)00866-4
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This systematic review and meta-analysis of 20 studies (2,551 patients) estimated the frequency of second primary malignant neoplasms (SPMs) after T-cell-engaging bispecific antibody (BsAb) therapy for B-cell non-Hodgkin lymphoma and multiple myeloma. At a median follow-up of 17.4 months, the pooled proportion of total SPMs was 3.5% (95% CI, 1.8-6.9), with 2.2% leading to treatment discontinuation and 1.4% to death. For clinicians managing cancer patients, these results quantify a measurable, clinically relevant long-term complication of a novel immunotherapy class now moving into earlier treatment lines. The findings underscore the need for standardized, extended safety surveillance and careful risk-benefit counseling when considering BsAb therapy.
10.1001/jamaoncol.2026.1859
Jun 08 – Jun 15, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This international multicenter retrospective study evaluated the efficacy of high-dose methotrexate (HD-MTX) for CNS prophylaxis in 1,923 patients with ultra high-risk (UHR) large B-cell lymphoma. Results showed no significant difference in the 3-year CNS relapse rate between patients receiving HD-MTX (8.1%) and those who did not (9.3%), with an adjusted hazard ratio of 1.13. Even in landmark analyses of responding patients, isolated CNS relapse rates remained comparable (5.7% vs 5.9%), suggesting no prophylactic benefit across any UHR subgroup. These findings challenge current international guidelines and suggest that HD-MTX prophylaxis may be omitted in most UHR patients, potentially reducing treatment-related toxicity without increasing relapse risk.
10.1200/JCO-26-00947
May 18 – May 25, 2026
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This phase 3 randomized trial evaluated tucidinostat plus R-CHOP versus R-CHOP alone in 423 patients with MYC/BCL2 double-expressor lymphoma (DEL), a high-risk DLBCL subtype. Median follow-up was 41.3 months; the combination reduced the risk of progression, relapse, or death by 28% (HR 0.72; 95% CI 0.54-0.96; P=0.02), with 2-year event-free survival of 60.3% vs 50.5%. Complete response rate improved from 61.8% to 73.0% (difference 11.1%; 95% CI 2.3%-20.0%), and toxicity was manageable. This provides a new first-line option for a poor-prognosis DEL population, directly addressing the clinician’s interest in cancer-focused research.
10.1001/jama.2026.4199
May 11 – May 18, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 3 trial investigated if adding autologous stem-cell transplantation (ASCT) to an ibrutinib-containing regimen improves outcomes in 870 younger mantle cell lymphoma patients. After 54.9 months, ibrutinib-containing groups (with or without ASCT) significantly improved 4-year failure-free survival (81-82% vs 70%) and overall survival (88-90% vs 81%) compared to ASCT alone. However, adding ASCT to ibrutinib offered no supplementary benefit but increased grade 3-5 adverse events (e.g., haematological disorders 54% vs 28%). Therefore, ibrutinib with immunochemotherapy and 2-year ibrutinib maintenance should be considered a new standard of care, potentially sparing patients from ASCT-related toxicity.
10.1016/S0140-6736(26)00362-4
Apr 27 – May 04, 2026
Adult T-Cell Leukemia/Lymphoma and Targeted Maternal Screening.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This population-based study analyzed US cancer registries (2005-2022) to estimate Adult T-cell leukemia/lymphoma (ATLL) incidence. It identified 3228 ATLL cases, finding non-Hispanic Caribbean-born US residents had an incidence rate of 14.1 per million, significantly higher than US/Canada-born populations (0.4 per million; IRR, 32.0), with rates peaking at 33.7 per million. Five-year survival was poor (23.8%), lowest among Caribbean-born individuals, highlighting a critical health disparity for this aggressive cancer. These findings identify early-life HTLV-1 infection as an actionable target for cancer prevention through maternal screening, with implications for reducing future ATLL burden.
10.1001/jamaoncol.2026.0859
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized, placebo-controlled trial evaluated whether prophylactic B-cell depletion with obinutuzumab could prevent corticosteroid-requiring chronic graft-versus-host disease (cGVHD) in 178 allogeneic transplant recipients. Obinutuzumab significantly reduced the 1-year incidence of steroid-requiring cGVHD to 13.3% compared to 35.2% in the placebo group (p=0.0005) and improved 2-year immunosuppression-free, relapse-free survival (48% vs. 34%). While the study focuses on a post-transplant complication, the findings are highly relevant for clinicians managing hematologic malignancies where cGVHD remains a major barrier to successful recovery. These results suggest that early B-cell depletion is an effective strategy for reducing morbidity and improving long-term outcomes in high-risk cancer patients undergoing transplantation.
10.1200/JCO-25-03104
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The TRANSFORM study (NCT03575351) compared lisocabtagene maraleucel (liso-cel) versus standard of care (ASCT) in 136 patients with second-line large B-cell lymphoma (LBCL), utilizing ultrasensitive circulating tumor DNA (ctDNA) to assess disease response. ctDNA clearance predicted longer event-free survival (EFS) in both arms, with significantly more liso-cel-treated patients achieving measurable residual disease (MRD) negativity. Liso-cel demonstrated superior outcomes, including longer EFS and progression-free survival (PFS), compared to ASCT, and ctDNA re-emergence predicted relapse. This research establishes ctDNA-MRD as a valuable prognostic biomarker beyond PET for treatment response and relapse prediction in LBCL, supporting its role in clinical practice.
10.1200/JCO-25-03051
Apr 20 – Apr 27, 2026
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This expert opinion paper reviews the diagnostic and therapeutic management of various hematologic malignancies diagnosed during pregnancy, addressing the increasing global incidence in this population. The authors evaluate the safety and efficacy of diagnostic modalities and treatment options, including chemotherapy, radiation therapy, and immunotherapy, for conditions such as acute leukemia and lymphomas. It provides clinical guidance on balancing maternal oncological care with fetal safety, emphasizing that more women are now receiving adequate treatment without compromising pregnancy outcomes. The findings suggest that multidisciplinary approaches allow for expanded treatment possibilities, though specific numerical survival data were not provided in this qualitative expert consensus.
10.1200/JCO-25-02351